New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects - PubMed (original) (raw)

• Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.
  Zumla A, Chakaya J, Centis R, D'Ambrosio L, Mwaba P, Bates M, Kapata N, Nyirenda T, Chanda D, Mfinanga S, Hoelscher M, Maeurer M, Migliori GB. Zumla A, et al. Lancet Respir Med. 2015 Mar;3(3):220-34. doi: 10.1016/S2213-2600(15)00063-6. Epub 2015 Mar 9. Lancet Respir Med. 2015. PMID: 25773212 Review.
• [Development of antituberculous drugs: current status and future prospects].
  Tomioka H, Namba K. Tomioka H, et al. Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
• Emerging drugs for the treatment of tuberculosis.
  Yew WW, Cynamon M, Zhang Y. Yew WW, et al. Expert Opin Emerg Drugs. 2011 Mar;16(1):1-21. doi: 10.1517/14728214.2011.521497. Epub 2010 Sep 26. Expert Opin Emerg Drugs. 2011. PMID: 20868293 Review.
• Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers.
  Wallis RS, Maeurer M, Mwaba P, Chakaya J, Rustomjee R, Migliori GB, Marais B, Schito M, Churchyard G, Swaminathan S, Hoelscher M, Zumla A. Wallis RS, et al. Lancet Infect Dis. 2016 Apr;16(4):e34-46. doi: 10.1016/S1473-3099(16)00070-0. Lancet Infect Dis. 2016. PMID: 27036358 Review.
• Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
  Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017; Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, Behera D, Benedetti A, Bisson GP, Boeree MJ, Bonnet M, Brode SK, Brust JCM, Cai Y, Caumes E, Cegielski JP, Centis R, Chan PC, Chan ED, Chang KC, Charles M, Cirule A, Dalcolmo MP, D'Ambrosio L, de Vries G, Dheda K, Esmail A, Flood J, Fox GJ, Fréchet-Jachym M, Fregona G, Gayoso R, Gegia M, Gler MT, Gu S, Guglielmetti L, Holtz TH, Hughes J, Isaakidis P, Jarlsberg L, Kempker RR, Keshavjee S, Khan FA, Kipiani M, Koenig SP, Koh WJ, Kritski A, Kuksa L, Kvasnovsky CL, Kwak N, Lan Z, Lange C, Laniado-Laborín R, Lee M, Leimane V, Leung CC, Leung EC, Li PZ, Lowenthal P, Maciel EL, Marks SM, Mase S, Mbuagbaw L, Migliori GB, Milanov V, Miller AC, Mitnick CD, Modongo C, Mohr E, Monedero I, Nahid P, Ndjeka N, O'Donnell MR, Padayatchi N, Palmero D, Pape JW, Podewils LJ, Reynolds I, Riekstina V, Robert J, Rodriguez M, Seaworth B, Seung KJ, Schnippel K, Shim TS, Singla R, Smith SE, Sotgiu G, Sukhbaatar G, Tabarsi P, Tiberi S, Trajman A, Trieu L, Udwadia ZF, van der Werf TS, Veziris N, Viiklepp P, Vilbrun SC,… See abstract for full author list ➔ Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017, et al. Lancet. 2018 Sep 8;392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1. Lancet. 2018. PMID: 30215381 Free PMC article. Review.